Aug 5, 2026 · 7 min
AI spending rattles SpaceX as Lilly powers higher
SanDisk Plunges, SpaceX Falls, Eli Lilly Jumps
The episode contrasts investor concern over capital-intensive AI ambitions with strong demand for Eli Lilly’s weight-loss drugs and the volatility of semiconductor stocks.
- 1SanDisk plunged 47% after earnings and guidance disappointed, despite remaining among the S&P 500’s strongest performers.
- 2SpaceX shares fell after its first earnings release as heavy artificial-intelligence capital expenditures unsettled investors.
- 3Eli Lilly jumped and raised its 2026 sales guidance on the strength of its weight-loss drug franchise.
Don't miss
Eli Lilly’s stock jumps as weight-loss drug success prompts the company to raise its 2026 sales guidance.
The brief
Stock Movers examines three post-market reversals: SanDisk’s 47% plunge, SpaceX’s decline after its first earnings release, and Eli Lilly’s sharp rise.
Hosts Tim Stanweck and Carol Massar speak with Bloomberg News equities reporter Avalon Purnell about how earnings, guidance, and analyst views shaped the market’s response.
SpaceX’s stock fell as investors weighed heavy artificial-intelligence capital expenditures, showing how ambitious growth spending can become a liability in public-market scrutiny.
SanDisk and Western Digital drew attention after earnings and guidance, while SanDisk’s steep drop stood out against its status as a top S&P 500 performer.
Eli Lilly offered the clearest positive surprise: strong weight-loss drug sales helped lift the stock and drove higher 2026 sales guidance.
What was said on this episode
4 statements · 1 positive · 3 negative
SanDisk forecast first-quarter revenue below expectations.
“the semiconductor maker forecast revenue for their first quarter that missed expectations quite a bit”
Listen at 1:29
SpaceX will need about $400 billion in funding to break even.
“SpaceX will need about $400 billion in funding to hit that break even point”
Listen at 3:50
SpaceX spending is unlikely to end soon.
“the spending doesn't exactly look like it's going to be ending anytime soon”
Listen at 3:56
Eli Lilly’s weight-loss drug sales exceeded expectations and boosted 2026 guidance.
“better than expected weight loss. Drug sales led to a boost in their 2026 guidance”
Listen at 4:50
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
SanDisk
Artificial IntelligenceListen to the full episode and explore every guest, topic, and moment on PodLume.